AtaiBeckley

Eli Lilly's acquisition of psychedelic drug maker AtaiBeckley signals growing pharmaceutical industry interest in psychedelic drugs for mental health treatment. The move reflects broader acceptance of this previously stigmatized medication class.

Eli Lilly will acquire a psychedelic drug developer for up to $3.8 billion, focusing on AtaiBeckley’s BPL-003 nasal spray in late-stage trials for treatment-resistant depression. Analysts project annual sales of $1-$2 billion if the drug succeeds. The company aims to leverage psychedelic chemicals for psychiatric treatments, though challenges in placebo-controlled trials and past industry scandals remain.

S&P 500 Index futures are down 0.2% as of 7:47 a.m. in New York. The US intensified strikes against Iran, hitting an oil tanker near the country’s main export terminal for the first time since the restart of the blockade on the Islamic Republic’s ports.

Eli Lilly is acquiring AtaiBeckley for $2.8 billion to gain access to experimental psychedelic drugs based on DMT and MDMA.